Complete AI Training
Start for Free

Your job's AI kit

Get your AI kit

Tell us who you are and what you do. We show you your kit right away and email you the link: skills, prompts, AI agents, MCP servers and courses for your job.

500+ jobs ready, and we make a kit for any other job. No payment needed to look.

Share

AI news ·

Prompt-to-Drug blueprint from Insilico and Lilly sets course for autonomous, end-to-end drug discovery

Insilico and Lilly outline an AI-orchestrated path from plain-language prompt to drug candidate. Linked bio, chem, and clinical modules, plus safeguards, point to quicker R&D.

From Prompt to Drug: A Practical Path to Fully Autonomous Pharmaceutical R&D

CAMBRIDGE, Mass. - February 20, 2026 - Insilico Medicine (3696.HK) and Lilly outlined a full-stack vision for autonomous, AI-orchestrated drug discovery in ACS Central Science. The perspective describes how generative AI, multimodal foundation models, and automated labs can be wired into a single, closed-loop workflow that moves from a plain-language request to a development-ready candidate.

The core issue they target is fragmentation. Today's R&D stacks mix powerful algorithms with manual, siloed experimentation. Their proposed "prompt-to-drug" framework connects target discovery, molecular design, synthesis, validation, and clinical planning under one controller that plans, delegates, and reviews work across specialized AI agents and lab systems.

What "Prompt-to-Drug" means

In this setup, a scientist could ask, "Design a drug for idiopathic pulmonary fibrosis," and a central reasoning engine would coordinate the entire pipeline. It would prioritize targets, generate and score structures, trigger automated synthesis and assays, interpret readouts, and adapt the plan-while preparing a clinically informed development strategy.

The paper traces how we got here: from classic machine learning to deep learning and transformers, with steady gains across target ID, generative chemistry, clinical prediction, and automated experimentation. The next step is stitching these pieces into a single, auditable system.

The architecture at a glance

  • Biology modules: Mine literature and omics, generate mechanistic hypotheses, and validate disease-relevant targets with in silico and in vitro loops.
  • Chemistry modules: Use generative chemistry, docking, free-energy calculations, and microfluidic synthesis to iteratively design and optimize compounds.
  • Clinical modules: Predict trial outcomes, patient subgroups, and protocol designs with engines like InClinico, feeding back constraints to upstream design.
  • AI orchestration: An advanced reasoning controller plans multi-step tasks, coordinates agents, tracks uncertainty, and revises strategies based on readouts.
  • Lab integration: APIs bridge AI agents with legacy equipment and humanoid-in-the-loop automation for uninterrupted, 24/7 workflows.

Safeguards and oversight

  • Hallucination and error control: Use retrieval grounding, consensus checks, and uncertainty thresholds before promoting results downstream.
  • Auditability: Full lineage of data, prompts, models, and decisions with versioned artifacts for regulatory review and internal QA.
  • Human oversight: Scientists review high-stakes gates (e.g., candidate selection, IND-enabling studies) and adjudicate conflicts.
  • Prospective validation: "AI arms" embedded in clinical trials to assess predictive tools in real-world settings without risking patient safety.
  • Governance: Bias monitoring, data-use controls, and security policies aligned with evolving guidance from agencies such as the FDA. See FDA's overview of AI/ML activities for context: FDA AI/ML.

Where the field stands today

Many building blocks already work at production scale. Insilico's DORA and PandaOmics sift literature and data to propose targets; Chemistry42 designs structures from user prompts using 3D context; its retrosynthesis module plans routes; and InClinico informs trial strategy. The paper shows how these steps, once linked under a unified controller, can shorten cycle times and reduce handoffs.

Automation fills the gaps. Microfluidic synthesis, programmatic docking and FEP, automated screening, and humanoid-in-the-loop systems keep work moving with fewer idle hours between chemistry and biology. The result is faster iteration with tighter feedback.

Selected peer-reviewed research cited

  • Target discovery: Journal of Chemical Information and Modeling - "PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery"
  • Target discovery: Aging - "Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine"
  • Generative chemistry: Nature Biotechnology - "Deep learning enables rapid identification of potent DDR1 kinase inhibitors"
  • Generative chemistry: Journal of Chemical Information and Modeling - "Chemistry42: An AI-Driven Platform for Molecular Design and Optimization"
  • Generative chemistry: Nature Biotechnology - "A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models"
  • Generative chemistry: Chemical Science - "nach0: multimodal natural and chemical languages foundation model"
  • Clinical: Nature Medicine - "A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial"
  • Clinical: Clinical Pharmacology & Therapeutics - "Prediction of Clinical Trials Outcomes Based on Target Choice and Clinical Trial Design with Multi-Modal Artificial Intelligence"

Performance signal

From 2021 to 2024, Insilico nominated 20 preclinical candidates. Average time from project start to PCC: 12-18 months, with just 60-200 molecules synthesized and tested per program-compared to typical early discovery timelines of 3-6 years.

What this means for R&D leaders and teams

  • Data readiness: Consolidate assay, structure, and clinical data with clear ontologies; capture negative results; enforce metadata standards.
  • Model ops: Treat foundation and task models as products-versioning, monitoring, drift checks, and reproducible pipelines.
  • Automation roadmap: Prioritize high-ROI steps (route planning, synthesis queues, primary screens) and expose instruments via stable APIs.
  • Closed-loop design: Define decision gates, uncertainty thresholds, and auto-escalation rules for human review.
  • Clinical integration: Feed trial constraints (population, dosing, endpoints) back to chemistry and biology cycles early.
  • Governance and security: Role-based access to data and models, audit trails by default, and protocol libraries for regulatory submissions.
  • Talent mix: Pair computational chemists and biologists with ML engineers, MLOps, and automation specialists.
  • KPIs: Time-per-iteration, prediction uplift vs. baselines, hit rate per synthesized compound, and cost per validated hypothesis.

Collaboration required

The authors argue the components exist, but true end-to-end autonomy needs coordination across academia, biotech, and regulators. Read the ACS Central Science perspective for the full framework and examples: From Prompt to Drug: Toward Pharmaceutical Superintelligence.

Note: The publication includes forward-looking statements. Outcomes depend on scientific, technical, and regulatory factors, and actual results may differ.

For further learning

Share